NCT03318562

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Effector Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy regimen for metastatic disease, and in male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed systemic therapy.

Conditions

• Triple Negative Breast Cancer
• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	eFT508	200 mg eFT508 dosed BID for 3 week cycles

Timeline

• Start date: 2017-11-21
• Primary completion: 2018-07-05
• Completion: 2019-01-22
• First posted: 2017-10-24
• Last updated: 2019-07-18

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study